

Brent M Kuenzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5636094/publications.pdf>

Version: 2024-02-01

17
papers

820
citations

687363

13
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

1569
citing authors

#	ARTICLE	IF	CITATIONS
1	Interpretation of cancer mutations using a multiscale map of protein systems. <i>Science</i> , 2021, 374, eabf3067.	12.6	29
2	Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer Cells. <i>Cancer Cell</i> , 2020, 38, 672-684.e6.	16.8	216
3	A census of pathway maps in cancer systems biology. <i>Nature Reviews Cancer</i> , 2020, 20, 233-246.	28.4	60
4	Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia. <i>Scientific Reports</i> , 2019, 9, 606.	3.3	21
5	The Galaxy Platform for Reproducible Affinity Proteomic Mass Spectrometry Data Analysis. <i>Methods in Molecular Biology</i> , 2019, 1977, 249-261.	0.9	4
6	An immunoproteomic approach to characterize the CAR interactome and signalosome. <i>Science Signaling</i> , 2019, 12, .	3.6	109
7	Ceritinib Enhances the Efficacy of Trametinib in <i>BRAF/NRAS</i> -Wild-Type Melanoma Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 73-83.	4.1	18
8	Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2796-2810.	4.1	26
9	Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 2434-2447.	3.8	17
10	Unraveling the rewired network. <i>Nature Chemical Biology</i> , 2018, 14, 746-747.	8.0	2
11	Polypharmacology-based ceritinib repurposing using integrated functional proteomics. <i>Nature Chemical Biology</i> , 2017, 13, 1222-1231.	8.0	60
12	Escape Excel: A tool for preventing gene symbol and accession conversion errors. <i>PLoS ONE</i> , 2017, 12, e0185207.	2.5	7
13	Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer. <i>Oncotarget</i> , 2017, 8, 103014-103031.	1.8	9
14	APOSTL: An Interactive Galaxy Pipeline for Reproducible Analysis of Affinity Proteomics Data. <i>Journal of Proteome Research</i> , 2016, 15, 4747-4754.	3.7	16
15	Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. <i>Cell Chemical Biology</i> , 2016, 23, 1490-1503.	5.2	80
16	Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer. <i>ACS Chemical Biology</i> , 2015, 10, 2680-2686.	3.4	68
17	GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells. <i>ACS Chemical Biology</i> , 2014, 9, 353-358.	3.4	76